Alzheimer's & Cognition
From the Journals
Younger age of type 2 diabetes onset linked to dementia risk
This new study is the first to examine the effect of diabetes in the relationship between prediabetes and dementia, as well as the age of diabetes...
Literature Review
Which interventions could lessen the burden of dementia?
The disappearance of hypertension alone from 2020 could decrease dementia prevalence by 21% in men and 16% in women.
From the Journals
Internet use a modifiable dementia risk factor in older adults?
“Online engagement can develop and maintain cognitive reserve – resiliency against physiological damage to the brain – and increased cognitive...
Literature Review
Deep sleep may mitigate the impact of Alzheimer’s pathology
“Think of deep sleep almost like a life raft that keeps memory afloat, rather than memory getting dragged down by the weight of Alzheimer’s...
FDA/CDC
FDA approves first drug to treat Alzheimer’s agitation
“Agitation is one of the most common and challenging aspects of care among patients with dementia due to Alzheimer’s disease.”
From the Journals
Hearing aids are a ‘powerful’ tool for reducing dementia risk
“The evidence is building that hearing loss may be the most impactful modifiable risk factor for dementia in mid-life.”
Guidelines
AHA backs screening for cognitive impairment after stroke
Cognitive impairment is common after a stroke; screening may help detect it early and allow appropriate multidisciplinary care, AHA says.
Conference Coverage
Oral antiamyloid shows disease-modifying potential Phase 3 trial underway
Phase 2 data showed that use of the drug resulted in positive changes in plasma and imaging biomarkers of Alzheimer’s disease pathology.
Conference Coverage
Donanemab bests aducanumab in head-to-head Alzheimer’s trial
Nearly 40% of patients treated with donanemab had amyloid clearance at 6 months compared with less than 2% of those who received aducanumab.
Conference Coverage
Cautious optimism for new Alzheimer’s disease biomarkers and treatments, expert says
“The greatest challenge is cost, as blood-based biomarkers are not currently covered by insurance and still rather costly.”
From the Journals
Unawareness of memory slips could indicate risk for Alzheimer’s
Over an 11-year study the people who declined in cognitive function were less aware of slips in their memory.